Fraunhofer-Institut für Produktionstechnologie IPT
Storys aus Aachen
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®
Aachen, Germany (ots) - - Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. - With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). - Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly ...
mehr- 2
Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients
mehr Fraunhofer-Institut für Produktionstechnologie IPT
5G Industry Campus Europe in Aachen expanded with Cloud RAN
mehr- 3
LAMILUX Continuous Rooflight B: Four new certifications
Ein Dokumentmehr Fraunhofer-Institut für Produktionstechnologie IPT
Hydrogen technologies at the Hannover Messe 2024: Fraunhofer IPT presents system designs for the production of bipolar plates, MEAs and pressure tanks
mehr- 2
agineo strengthens its international presence with new branches in Europe
mehr Fraunhofer-Institut für Produktionstechnologie IPT
Fraunhofer study report describes AI use cases and sustainable energy concepts
mehrFraunhofer-Institut für Produktionstechnologie IPT
Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems
mehrBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
mehrBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
Fraunhofer IPT conducts research into automated series production of optics with new glass press
mehrGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
Fraunhofer study report on cybersecurity, digital twins and sustainability in production
mehr- 4
Steigenberger Hotels & Resorts brand coming to Bielefeld
Ein Dokumentmehr Empowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced
Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...
mehrGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
Joint expertise from industry and research: New regulations standardize optical coherence tomography
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehrFraunhofer-Institut für Produktionstechnologie IPT
Go-ahead for 6G in industry: EU funds technology development with more than 13 million euros
mehrFraunhofer-Institut für Produktionstechnologie IPT
Fraunhofer IPT manufactures super-lightweight frame for experiments in outer space
mehrJanneke van der Kamp starts as new Chief Commercial Officer at Grünenthal
mehrJanneke van der Kamp joins Grünenthal as new Chief Commercial Officer
mehrGrünenthal closes deal to acquire testosterone therapy NebidoTM from Bayer for €495 million
Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency affects one in six men over 50 years1; representing a significant burden," said Gabriel Baertschi, CEO Grünenthal. "With the completion of this deal, we can now work to bring this meaningful treatment to ...
mehrHDI TH!NX makes battery reliability insurable on the basis of ACCURE battery analytics
mehrGrünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
Aachen, Germany (ots) - - Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovative non-opioid investigational medicine. - The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. - Globally, more than 300 million patients ...
mehrBVG Trials ACCURE’s Battery Safety Monitoring System on Electric Buses
mehrACCURE exceeds 1,111 megawatt-hours of monitored battery systems with battery-powered boats from Soel Yachts and Naval DC
mehrLegalization debate in Germany: Cannabis expert Cannify becomes Enua Pharma GmbH / The start-up has been on the market for four years and is now one of the largest cannabis retailers in Germany
mehrACCURE raises $8 million dollars to accelerate the battery safety and analytics market
mehr